It recorded a net loss of $3.1 million. Diluted earnings per share were -$0.02. Over the twelve months ended Dec 31, 2022, revenue was $2.7 million and the net loss was $2.0 million. Across the 7 fiscal years shown, revenue grew from $818,583 in fiscal 2016 to $2.7 million in fiscal 2022, about 22.0% a year.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2023
Dec 31, 2022
|
FY 2025
Sep 30, 2025
|
FY 2024
Sep 30, 2024
|
FY 2023
Sep 30, 2023
|
FY 2022
Sep 30, 2022
|
FY 2021
Sep 30, 2021
|
FY 2020
Sep 30, 2020
|
FY 2019
Sep 30, 2019
|
FY 2018
Sep 30, 2018
|
FY 2017
Sep 30, 2017
|
FY 2016
Sep 30, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3
+0.9%
|
—
|
—
|
—
|
3
+7.8%
|
3
-2.7%
|
3
+0.9%
|
3
-10.1%
|
3
+49.6%
|
2
+131.9%
|
1
+4989.4%
|
| Cost of revenue |
2
-8.7%
|
—
|
—
|
—
|
2
-8.6%
|
2
+0.6%
|
2
+3.8%
|
2
-17.3%
|
2
+128.9%
|
1
+137.9%
|
0
+344.2%
|
| Gross profit |
1
+19.7%
|
—
|
—
|
—
|
1
+49.0%
|
1
-10.1%
|
1
-5.2%
|
1
+9.1%
|
1
-22.5%
|
1
+126.7%
|
0
+731.3%
|
| Selling, general and administrative |
0
-69.0%
|
1
+50.1%
|
1
+813.6%
|
0
-79.2%
|
0
-46.9%
|
1
-37.0%
|
1
-11.4%
|
2
-18.6%
|
2
+63.5%
|
1
-0.2%
|
1
-19.4%
|
| Operating income |
-1
-62.1%
|
-3
-64.3%
|
-2
-317.7%
|
-0
+62.0%
|
-1
-48.9%
|
-1
+64.8%
|
-2
-18.9%
|
-2
-4.8%
|
-2
-35.6%
|
-1
+55.0%
|
-3
+16.2%
|
| Interest expense |
—
|
0
-47.4%
|
0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Pretax income |
—
|
-3
-128.7%
|
-1
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Income tax |
—
|
—
|
0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Net income |
-2
-252.2%
|
-3
-294.9%
|
-1
-418.3%
|
0
+112.0%
|
-2
-199.7%
|
-1
+70.3%
|
-2
-27.9%
|
-2
-9.2%
|
-2
-55.3%
|
-1
+71.2%
|
-4
+14.6%
|
| Basic EPS |
—
|
-0.02
-100.0%
|
-0.01
|
0.00
+100.0%
|
-0.03
|
—
|
—
|
—
|
—
|
—
|
—
|
| Diluted EPS |
—
|
-0.02
-100.0%
|
-0.01
|
0.00
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Weighted average shares, basic |
—
|
135
+33.3%
|
101
+20.8%
|
84
+13.1%
|
74
|
—
|
—
|
—
|
—
|
—
|
—
|
| Weighted average shares, diluted |
—
|
135
+33.3%
|
101
+20.8%
|
84
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Other measures | |||||||||||
| Depreciation and amortization |
—
|
0
+934.2%
|
0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| EBITDA |
—
|
-3
-63.8%
|
-2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Interest coverage |
—
|
-28.28x
|
-9.06x
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Margins | |||||||||||
| Gross margin |
40.08%
|
—
|
—
|
—
|
39.48%
|
28.56%
|
30.91%
|
32.90%
|
27.12%
|
52.37%
|
53.57%
|
| Operating margin |
-38.14%
|
—
|
—
|
—
|
-42.61%
|
-30.85%
|
-85.16%
|
-72.21%
|
-61.93%
|
-68.34%
|
-352.13%
|
| Profit margin |
-74.07%
|
—
|
—
|
—
|
-76.19%
|
-27.42%
|
-89.71%
|
-70.73%
|
-58.23%
|
-56.11%
|
-451.88%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Services-Testing Laboratories (SIC 8734)
- Listed as
- FUNI (OTC)
- Fiscal year ends
- September 30
- Incorporated in
- NV
- Headquarters
- Las Vegas, NV
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1502966
- Former names
- Digipath, Inc. (until Mar 1, 2024); DigiPath,Inc. (until Sep 18, 2018)
Other Services-Testing Laboratories companies
- UL Solutions Inc. ULS
- Neogenomics Inc NEO
- 20/20 Biolabs, Inc. AIDX
Source: SEC EDGAR filings. This is company-reported data, not investment advice.